Project Grant R43NS093724

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $387,500.00 to Texas Tech University Health Sciences Center (TTUHSC) to develop novel small molecule inhibitors targeting the EphB1/2 tyrosine kinase signaling pathway and evaluate their efficacy in mitigating peripheral neuropathic pain. The 5-year project aims to (1) develop...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $1,510,066 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to The University of Kentucky Research Foundation to conduct a planning study for the development of sigma 2 ligands as novel analgesics for chronic neuropathic pain. The funding will support an interdisciplinary research team to: (1) develop an in-silico library of potential sigma 2 ligand analogs, (2) synthesize and evaluate...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support the development of novel angiotensin AT2 receptor inhibitors for the treatment of neuropathic pain. The $818,360 award to the University of Southern California will fund research to optimize lead compounds showing improved potency, efficacy, and safety profiles compared...

This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7...

Regulonix LLC was awarded a $1,258,410 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), to support research under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). Through this one-year award ending August 31, 2022, Regulonix will partner with the University of Arizona to characterize inhibitors of the neuropilin-1 (NRP-1) receptor for potential...

This Project Grant award of $650,079 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to develop selective probes targeting the α9 nicotinic acetylcholine receptor (α9*-nAChR) for treating chronic inflammatory and neuropathic pain. The key objectives are to: 1) Develop small-molecule agonists and antagonists of α9*-nAChR through structure-activity...

This $675,107 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders supports research by Northeastern University to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The key objectives are to: 1) design and synthesize new cannabinoid CB1 receptor allosteric agonist-positive allosteric modulator (CB1R AGO-PAM) and CB2 receptor...

This Project Grant award, with a total funding amount of $664,772, was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The award supports research to investigate the signaling mechanisms involving the neurotensin receptor 2 (NTSR2) and voltage-gated calcium channels (Cav2.3 and Cav2.2) as a novel, non-opioid analgesic pathway for the...